PHILADELPHIA — Patients with neovascular age-related macular degeneration receiving intravitreal anti-VEGF injections should be encouraged to adhere to their treatment regimen, according to a speaker at the Wills Eye Conference.
“Eyes with neovascular AMD receiving intravitreal anti-VEGF who are lost to follow-up and then return experience significant visual acuity decline at the return visit that persists upon the final visit,” Rebecca Russ Soares, MD, MPH, said.
Building on a study by Obeid and colleagues that demonstrated 22.2% of 9,007 patients did not return for a
Uncategorized